Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

索拉非尼 医学 内科学 打开标签 肝细胞癌 肿瘤科 一线治疗 临床终点 随机对照试验 化疗
作者
Shukui Qin,Feng Bi,Shanzhi Gu,Yuxian Bai,Zhendong Chen,Zishu Wang,Jieer Ying,Yinying Lu,Zhiqiang Meng,Hongming Pan,Ping Yang,Helong Zhang,Xi Chen,Aibing Xu,Chengxu Cui,Bo Zhu,Jian Wu,Xiaoli Xin,Jufeng Wang,Jinlu Shan
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (27): 3002-3011 被引量:450
标识
DOI:10.1200/jco.21.00163
摘要

PURPOSE Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study compared the efficacy and safety of donafenib versus sorafenib as first-line therapy for advanced HCC. PATIENTS AND METHODS This open-label, randomized, parallel-controlled, multicenter phase II-III trial enrolled patients with unresectable or metastatic HCC, a Child-Pugh score ≤ 7, and no prior systemic therapy from 37 sites across China. Patients were randomly assigned (1:1) to receive oral donafenib (0.2 g) or sorafenib (0.4 g) twice daily until intolerable toxicity or disease progression. The primary end point was overall survival (OS), tested for noninferiority and superiority. Efficacy was primarily assessed in the full analysis set (FAS), and safety was assessed in all treated patients. RESULTS Between March 21, 2016, and April 16, 2018, 668 patients (intention-to-treat) were randomly assigned to donafenib and sorafenib treatment arms; the FAS included 328 and 331 patients, respectively. Median OS was significantly longer with donafenib than sorafenib treatment (FAS; 12.1 v 10.3 months; hazard ratio, 0.831; 95% CI, 0.699 to 0.988; P = .0245); donafenib also exhibited superior OS outcomes versus sorafenib in the intention-to-treat population. The median progression-free survival was 3.7 v 3.6 months ( P = .0570). The objective response rate was 4.6% v 2.7% ( P = .2448), and the disease control rate was 30.8% v 28.7% (FAS; P = .5532). Drug-related grade ≥ 3 adverse events occurred in significantly fewer patients receiving donafenib than sorafenib (125 [38%] v 165 [50%]; P = .0018). CONCLUSION Donafenib showed superiority over sorafenib in improving OS and has favorable safety and tolerability in Chinese patients with advanced HCC, showing promise as a potential first-line monotherapy for these patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
改善发布了新的文献求助10
刚刚
1秒前
1秒前
1秒前
zhxh发布了新的文献求助30
1秒前
1秒前
四季西瓜发布了新的文献求助10
1秒前
中雨发布了新的文献求助10
1秒前
KKK完成签到 ,获得积分10
1秒前
烟花的应助被何胤辰采纳,获得10
2秒前
屁屁完成签到,获得积分20
2秒前
野生大型皮皮完成签到,获得积分10
2秒前
限时达发布了新的文献求助10
2秒前
科研通AI6.3的应助被corleeang采纳,获得10
2秒前
bkagyin的应助被年轻觅山采纳,获得10
2秒前
六六发布了新的文献求助10
3秒前
星1993发布了新的文献求助10
3秒前
4秒前
4秒前
Present发布了新的文献求助30
5秒前
5秒前
指尖发布了新的文献求助10
5秒前
Lily发布了新的文献求助10
5秒前
科研通AI6.2的应助被什米采纳,获得10
5秒前
深情安青的应助被友好的诗筠采纳,获得10
5秒前
6秒前
6秒前
Cheryl发布了新的文献求助10
7秒前
li完成签到,获得积分10
7秒前
ddddd完成签到,获得积分10
7秒前
7秒前
9秒前
9秒前
春申君发布了新的文献求助10
9秒前
ding的应助被天真的日记本采纳,获得10
10秒前
10秒前
11秒前
七月流火的应助被rapamycin采纳,获得10
11秒前
舒适雪糕完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124